Post drug pricing controls shall be wholly reviewed

By taking a chance for the public hearing at the National Assembly Health and Welfare Committee the pharmaceutical industry raised strong opinions that the current post drug pricing control policy should be entirely reviewed, viewing that the policy has reflected mainly the bottom prices by inspecting actual transacted drug prices in the market.

In the public hearing at the National Assembly...